Trial Profile
Effects of Dabigatran in Patients With AF - A Prospective, Randomized, Open-label, Explorative, Blinded-endpoint Trial to Compare the Efficacy of Dabigatran With Phenprocoumon for the Resolution of LAA Thrombus in Patients With AF
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Phenprocoumon
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms RE-LATED AF
- 06 Jul 2018 Status changed from recruiting to discontinued.
- 26 Feb 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018, according to ClinicalTrials.gov record.
- 26 Feb 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018, according to ClinicalTrials.gov record.